IL15 and neoplasm: To characterize the transcriptional state of the NCI-meso63 tumors during therapy with MSLN.CAR-IL-15 iNK cells, as well as that of tumor-infiltrating MSLN.CAR-IL-15 iNK cells, we performed single-cell RNA-seq (scRNA-seq) on total cells isolated from untreated tumors (three samples), iNK-treated tumors (three samples) (same harvest on day 7 post–MSLN.CAR-IL-15 GR1.1-iNK treatment as shown in Fig. 6A), and MSLN.CAR-IL-15 GR1.1-iNK preinfusion product (two samples) (Fig. 7A).